SpyGlass Pharma Q2 Loss Widens
(RTTNews) - SpyGlass Pharma Inc. (SGP) on Thursday reported a wider second-quarter net loss as research and administrative expenses increased.
Net loss widened to $19.9 million, or $0.59 per share, from $8.7 million, or $3.81 per share, in the prior-year quarter.
Research and development expenses rose to $10.9 million from $7.3 million, while general and administrative expenses increased to $11.0 million from $2.0 million.
Looking ahead, SpyGlass expects to initiate the first-in-human trial of its Bimatoprost Drug Ring System, or BIM-DRS, in the second half of 2026 and report four-year efficacy and safety follow-up data for the BIM-IOL System in the fourth quarter of 2026.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.